Aktienanalyse zu Achieve Life Sciences, Inc. (ACHV)ACHVAchieve Life Sciences, Inc.

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Achieve Life Sciences Inc is a good buy right now due to its current price of $8.10, which is significantly below the analyst price targets of $13 and $18, indicating a potential upside of 60% to 122%. Additionally, the stock has shown strong momentum with a 20-day change of +26.17% and a 1-year change of +177.40%. However, the main risk is the negative net income of -74,769,000 USD reported in Q2 2026, which reflects ongoing financial challenges.

1 analysts cover ACHV: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 15.50.